Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 177

1.

Sulfated polysaccharide, curdlan sulfate, efficiently prevents entry/fusion and restricts antibody-dependent enhancement of dengue virus infection in vitro: a possible candidate for clinical application.

Ichiyama K, Gopala Reddy SB, Zhang LF, Chin WX, Muschin T, Heinig L, Suzuki Y, Nanjundappa H, Yoshinaka Y, Ryo A, Nomura N, Ooi EE, Vasudevan SG, Yoshida T, Yamamoto N.

PLoS Negl Trop Dis. 2013 Apr 25;7(4):e2188. doi: 10.1371/journal.pntd.0002188.

2.

Antibody-dependent enhancement of dengue virus infection is inhibited by SA-17, a doxorubicin derivative.

Ayala-Nuñez NV, Jarupathirun P, Kaptein SJ, Neyts J, Smit JM.

Antiviral Res. 2013 Oct;100(1):238-45. doi: 10.1016/j.antiviral.2013.08.013.

PMID:
23994499
3.

Mechanism of the inhibitory effect of curdlan sulfate on HIV-1 infection in vitro.

Jagodzinski PP, Wiaderkiewicz R, Kurzawski G, Kloczewiak M, Nakashima H, Hyjek E, Yamamoto N, Uryu T, Kaneko Y, Posner MR, et al.

Virology. 1994 Aug 1;202(2):735-45.

PMID:
7913276
4.

Interference in dengue virus adsorption and uncoating by carrageenans.

Talarico LB, Damonte EB.

Virology. 2007 Jul 5;363(2):473-85.

5.

Identification of a new dengue virus inhibitor that targets the viral NS4B protein and restricts genomic RNA replication.

van Cleef KW, Overheul GJ, Thomassen MC, Kaptein SJ, Davidson AD, Jacobs M, Neyts J, van Kuppeveld FJ, van Rij RP.

Antiviral Res. 2013 Aug;99(2):165-71. doi: 10.1016/j.antiviral.2013.05.011.

PMID:
23735301
6.

Unfolded protein response (UPR) gene expression during antibody-dependent enhanced infection of cultured monocytes correlates with dengue disease severity.

Paradkar PN, Ooi EE, Hanson BJ, Gubler DJ, Vasudevan SG.

Biosci Rep. 2011 Jun;31(3):221-30. doi: 10.1042/BSR20100078.

PMID:
20858223
7.

3-O-sulfated glucuronide derivative as a potential anti-dengue virus agent.

Hidari KI, Ikeda K, Watanabe I, Abe T, Sando A, Itoh Y, Tokiwa H, Morita K, Suzuki T.

Biochem Biophys Res Commun. 2012 Aug 3;424(3):573-8. doi: 10.1016/j.bbrc.2012.07.002.

PMID:
22776202
8.

Viral entry inhibitors block dengue antibody-dependent enhancement in vitro.

Nicholson CO, Costin JM, Rowe DK, Lin L, Jenwitheesuk E, Samudrala R, Isern S, Michael SF.

Antiviral Res. 2011 Jan;89(1):71-4. doi: 10.1016/j.antiviral.2010.11.008.

PMID:
21093488
9.

Peptide inhibitors against dengue virus infection.

Panya A, Bangphoomi K, Choowongkomon K, Yenchitsomanus PT.

Chem Biol Drug Des. 2014 Aug;84(2):148-57. doi: 10.1111/cbdd.12309.

PMID:
24612829
10.

Manipulation of immunodominant dengue virus E protein epitopes reduces potential antibody-dependent enhancement.

Hughes HR, Crill WD, Chang GJ.

Virol J. 2012 Jun 18;9:115. doi: 10.1186/1743-422X-9-115.

11.

Dengue Virus prM-Specific Human Monoclonal Antibodies with Virus Replication-Enhancing Properties Recognize a Single Immunodominant Antigenic Site.

Smith SA, Nivarthi UK, de Alwis R, Kose N, Sapparapu G, Bombardi R, Kahle KM, Pfaff JM, Lieberman S, Doranz BJ, de Silva AM, Crowe JE Jr.

J Virol. 2015 Oct 28;90(2):780-9. doi: 10.1128/JVI.01805-15.

12.

Antiviral activity of carbohydrate-binding agents and the role of DC-SIGN in dengue virus infection.

Alen MM, Kaptein SJ, De Burghgraeve T, Balzarini J, Neyts J, Schols D.

Virology. 2009 Apr 25;387(1):67-75. doi: 10.1016/j.virol.2009.01.043.

13.
14.

Narasin, a novel antiviral compound that blocks dengue virus protein expression.

Low JS, Wu KX, Chen KC, Ng MM, Chu JJ.

Antivir Ther. 2011;16(8):1203-18. doi: 10.3851/IMP1884.

PMID:
22155902
15.

An analogue of the antibiotic teicoplanin prevents flavivirus entry in vitro.

De Burghgraeve T, Kaptein SJ, Ayala-Nunez NV, Mondotte JA, Pastorino B, Printsevskaya SS, de Lamballerie X, Jacobs M, Preobrazhenskaya M, Gamarnik AV, Smit JM, Neyts J.

PLoS One. 2012;7(5):e37244. doi: 10.1371/journal.pone.0037244.

16.

Autophagy facilitates antibody-enhanced dengue virus infection in human pre-basophil/mast cells.

Fang YT, Wan SW, Lu YT, Yao JH, Lin CF, Hsu LJ, Brown MG, Marshall JS, Anderson R, Lin YS.

PLoS One. 2014 Oct 16;9(10):e110655. doi: 10.1371/journal.pone.0110655.

17.

Dengue virus type 2 envelope protein displayed as recombinant phage attachment protein reveals potential cell binding sites.

Abd-Jamil J, Cheah CY, AbuBakar S.

Protein Eng Des Sel. 2008 Oct;21(10):605-11. doi: 10.1093/protein/gzn041.

PMID:
18669522
18.

The kinase inhibitor SFV785 dislocates dengue virus envelope protein from the replication complex and blocks virus assembly.

Anwar A, Hosoya T, Leong KM, Onogi H, Okuno Y, Hiramatsu T, Koyama H, Suzuki M, Hagiwara M, Garcia-Blanco MA.

PLoS One. 2011;6(8):e23246. doi: 10.1371/journal.pone.0023246.

20.

Antiviral activity of chondroitin sulphate E targeting dengue virus envelope protein.

Kato D, Era S, Watanabe I, Arihara M, Sugiura N, Kimata K, Suzuki Y, Morita K, Hidari KI, Suzuki T.

Antiviral Res. 2010 Nov;88(2):236-43. doi: 10.1016/j.antiviral.2010.09.002.

PMID:
20851716

Supplemental Content

Support Center